US EditionSibeprenlimab’s Potential in IgA Nephropathy, with John Kraus, MD, PhD
Summary by hcplive.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
All
Left
Center
Right
Yes, I CAN: Learn About a Clinical Research Study for IgA Nephropathy (IgAN) – Patient Worthy
Acknowledgment: This story is sponsored by Alexion Pharmaceuticals and is promoted through the Patient Worthy Collaborative Content program. We only publish content that embodies our mission of providing relevant, vetted, and valuable information to the rare disease community. A clinical research study is now underway to study the safety and effectiveness of a study medication […]
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
